Savara Inc Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest
Savara Inc (SVRA) had Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest of -$534.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest
us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest · last filed 2026-08-11
- 2026-06-30: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest -$534.00K.
- 2026-03-31: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest -$429.00K.
- 2025-12-31: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest -$87.00K.
- 2025-09-30: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest -$155.00K.
| Period end | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest |
|---|---|
| 2026-06-30 | -$534.00K 10-Q · filed 2026-08-11 |
| 2026-03-31 | -$429.00K 10-Q · filed 2026-05-12 |
| 2025-12-31 | -$87.00K 10-Q · filed 2026-08-11 |
| 2025-09-30 | -$155.00K 10-Q · filed 2025-11-12 |
| 2025-06-30 | -$216.00K 10-Q · filed 2025-08-13 |
| 2025-03-31 | -$632.00K 10-Q · filed 2025-05-13 |
| 2024-12-31 | -$750.00K 10-Q · filed 2026-08-11 |
| 2024-09-30 | $299.00K 10-Q · filed 2024-11-12 |
| 2024-06-30 | -$880.00K 10-Q · filed 2024-08-12 |
| 2024-03-31 | -$742.00K 10-Q · filed 2024-05-09 |
| 2023-12-31 | -$271.00K 10-K · filed 2026-03-13 |
| 2023-09-30 | -$942.00K 10-Q · filed 2023-11-09 |
| 2023-06-30 | -$619.00K 10-Q · filed 2023-08-10 |
| 2023-03-31 | -$461.00K 10-Q · filed 2023-05-15 |
| 2022-12-31 | -$605.00K 10-K · filed 2025-03-27 |
| 2022-09-30 | -$1.61M 10-Q · filed 2022-11-10 |
| 2022-06-30 | -$1.02M 10-Q · filed 2022-08-11 |
| 2022-03-31 | -$291.00K 10-Q · filed 2022-05-11 |
| 2021-12-31 | $5.00K 10-K · filed 2024-03-07 |
| 2021-09-30 | $285.00K 10-Q · filed 2021-11-12 |
| 2021-06-30 | $592.00K 10-Q · filed 2021-08-12 |
| 2021-03-31 | $485.00K 10-Q · filed 2021-05-13 |
| 2020-12-31 | $942.00K 10-K · filed 2023-03-30 |
| 2019-12-31 | -$17.00K 10-K · filed 2022-03-30 |
| 2018-12-31 | $200.00K 10-K · filed 2021-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B |